Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

@article{Haber2015PostlicensureSO,
  title={Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.},
  author={Penina Haber and Pedro Moro and Mar{\'i}a Victoria Moreno Cano and Paige W Lewis and Brock Stewart and Tom T Shimabukuro},
  journal={Vaccine},
  year={2015},
  volume={33 16},
  pages={1987-92}
}
BACKGROUND Quadrivalent live attenuated influenza vaccine (LAIV4) was approved in 2012 for healthy persons aged 2-49 years. Beginning with the 2013-2014 influenza season, LAIV4 replaced trivalent live attenuated influenza vaccine (LAIV3). METHODS We analyzed LAIV4 reports to VAERS, a national spontaneous reporting system. LAIV4 reports in 2013-2014 were compared to LAIV3 reports from the previous three influenza seasons. Medical records were reviewed for non-manufacturer serious reports (i.e… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

FluMist® Package Insert (circular)

  • MedImmune, INC
  • http://www. medimmune.com/docs/default-source…
  • 2013
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…